2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2521 Impact of parous female donors on haploidentical hematopoietic stem cell transplantation outcomes in patients with severe aplastic anemia

Zhengwei Tan, MD, Nanxi Dong, MD2, Nana Zhou3, Hangchao Li4, Dijiong Wu, MD,PhD5, Baodong Ye, MD, PhD6, Wenbin Liu, MD,PhD7
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China

Background: Parous female donors (PFDs), sensitized to paternal HLA alloantigens during gestation, have been associated with an elevated risk of acute graft-versus-host disease (GVHD) and non-relapse mortality in hematologic malignancies, a phenomenon termed the "PFD effect". Whether the PFD effect significantly modulates transplant outcomes in severe aplastic anemia (SAA), a non-malignant condition dependent on durable engraftment and minimal GVHD, remains incompletely defined.

Methods: We conducted a retrospective cohort analysis of 156 consecutive SAA patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT) at a single center between January 2018 and December 2024. Patients were stratified into three groups: parous female donor (PFD, n=22), nulliparous female donor (NFD, n=44), and young male donor (YMD, n=90). The primary endpoints were overall survival (OS) and GVHD-free/relapse-free survival (GRFS). Secondary endpoints included engraftment, primary graft failure, acute and chronic GVHD, and CMV/EBV reactivation. Multivariable Cox proportional hazards regression was performed to adjust for confounders.

Results: Hematopoietic engraftment was comparable across the three groups. The cumulative incidence of any-grade aGVHD was marginally higher in the PFD (54.5%) and NFD (50.0%) groups than in the YMD group (32.2%; p=0.049), but grade II-IV aGVHD and cGVHD did not differ significantly. At a median follow-up of 19 months, 3-year OS was 77.2% for PFD, 88.6% for NFD, and 73.3% for YMD. In multivariable analysis, NFDs were an independent protective factor for OS compared with YMDs (HR 0.35; 95%CI 0.18-0.69; p=0.002), whereas PFDs were independently associated with inferior OS (HR 1.62; 95%CI 1.15-2.28; p=0.006). Very severe aplastic anemia (HR 1.68; p=0.012) and donor-specific antibody positivity (HR 1.85; p<0.001) were also independent risk factors, while the FABT regimen was protective (HR 0.55; p<0.001).

Conclusions: In SAA patients receiving haplo-HSCT, the classical PFD effect persists in the non-malignant setting, with PFDs conferring independently worse OS and NFDs conferring a survival advantage. These findings indicate that donor parity and age, rather than parity alone, represent actionable determinants of transplant success and should inform risk-adapted donor selection strategies.

Wenbin Liu, MD,PhD: No relevant conflicts of interest to declare.